Trial · NCT03417102

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

NCT03417102, Phase 3, Completed, Genzyme, a Sanofi Company; results first posted 2021-12-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors. Trials, record NCT03417102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03417102

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
NCT number: NCT03417102
Status: Completed
Phases: Phase 3
Enrollment: 60 participants, actual
Lead sponsor: Genzyme, a Sanofi Company
Conditions: Hemophilia A, Hemophilia B
Interventions: fitusiran, Bypassing agents
First posted: 2018-01-31
Last updated: 2022-03-28
Other registries' IDs: eudract:2016-001463-36
Results first posted: 2021-12-21

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	ABR for a participant during efficacy period (EP) was defined as annualized number of bleeding episodes during EP annualized to a 1-year interval of time. Treated Bleeding episode: any occurrence of hemorrhage that required administration of BPA or factor. It started from first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP was defined as time duration starting from Day 29 when antithrombin (AT) lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This outcome measure (OM) represents estimated results (i.e., results received by applying negative binomial \[NB\] regression model on data collected during EP).
Primary	Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	ABR for a participant during EP was defined as annualized number of bleeding episodes during EP annualized to a 1-year interval of time. ABR= number of bleeding episodes during EP divided by total number of days during EP\*365.25. A bleeding episode was defined as any occurrence of hemorrhage that required administration of BPA or factor. It started from the first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP was defined as time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or the last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM represents observed results (i.e., descriptive statistics values based on the data which was collected during EP).
Secondary	Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	From Day 1 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	ABR for a participant during treatment period (TP) was defined as annualized number of bleeding episodes during TP annualized to a 1-year interval of time. Bleeding episode: any occurrence of hemorrhage that required administration of BPA or factor. It started from first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. TP was sum of onset period (first 28 days after first dose of fitusiran) and EP (starting on Day 29 when AT lowering capacity of fitusiran had achieved therapeutic target range to earliest of \[Day 246 or last day of bleeding follow up\])(maximum duration of TP: from Day 1 to Day 246). This OM represents estimated results (i.e., results received by applying NB regression model on data collected during TP).
Secondary	Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	From Day 1 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	ABR for a participant during TP was defined as annualized number of bleeding episodes during TP annualized to a 1-year interval of time. ABR= number of bleeding episodes during TP divided by total number of days during TP\*365.25. Bleeding episode: any occurrence of hemorrhage that required administration of BPA or factor. It started from the first sign of a bleed and ended no more than 72 hours after last treatment for bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. TP was sum of onset period (first 28 days after the first dose of fitusiran) and EP (starting on Day 29 when AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of \[Day 246 or the last day of bleeding follow up\]) (maximum duration of TP: from Day 1 to Day 246). This OM represents observed results (i.e., descriptive statistics values based on data collected during TP).
Secondary	Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Annualized spontaneous bleeding rate for a participant during EP was defined as annualized number of spontaneous bleeding episodes during EP annualized to a 1-year interval of time. Spontaneous bleeding episode was bleeding event that occurred for no apparent or known reason, particularly into joints, muscles, and soft tissues. It started from first sign of a bleed and ended no more than 72 hours after last treatment for the bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP was defined as time duration starting from Day 29 when AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM represents estimated results (i.e., results received by applying NB regression model on data collected during EP).
Secondary	Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	ABR for participant during EP was defined as annualized number of spontaneous bleeding episodes during EP annualized to a 1-year interval of time. ABR=number of treated spontaneous bleeding episodes during EP divided by total number of days during EP\*365.25. Spontaneous bleeding episode was bleeding event that occurred for no apparent or known reason, into joints, muscles, and soft tissues. It started from the first sign of a bleed and ended no more than 72 hours after the last treatment for bleed, within which any symptoms of bleeding at the same location or injections less than or equal to 72 hours apart were considered the same bleeding episode. EP: time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to earliest of (Day 246 or the last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM represents observed results (i.e., descriptive statistics values based on data collected during EP).
Secondary	Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Annualized joint bleeding rate for a participant during EP was defined as annualized number of bleeding episodes during EP annualized to a 1-year interval of time. Joint bleeding episode was characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin, joint, 2) increased pain, or 3) progressive loss of range of motion or difficulty in using the limb as compared with Baseline. It started from first sign of a bleed and ended no more than 72 hours after last treatment for the bleed. EP was defined as time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or the last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM presents estimated results (i.e., results received by applying NB regression model on data collected during EP).
Secondary	Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Annualized joint bleeding rate for participant during EP was defined as annualized number of joint bleeding episodes during EP annualized to 1-year interval of time. ABR= number of treated joint bleeding episodes during EP divided by total number of days during EP\*365.25. A joint bleeding episode was characterized by an unusual sensation in joint ("aura") in combination with 1) increasing swelling or warmth over skin, joint, 2) increased pain, or 3) progressive loss of range of motion or difficulty in using limb as compared with Baseline. It started from first sign of a bleed and ended no more than 72 hours after the last treatment for the bleed. EP: time duration starting from Day 29 when the AT lowering capacity of fitusiran had achieved therapeutic target range to the earliest of (Day 246 or last day of bleeding follow up) (maximum duration of EP: from Day 29 to Day 246). This OM presents observed results (i.e., descriptive statistics values based on data collected during EP).
Secondary	Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Month 9	Baseline (Day 1), Month 9	Haem-A-QoL: participant-reported questionnaire designed for adult participants (\>=17 years of age) with hemophilia; and consisted of 46 items comprising 10 domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Items were rated along five response options: never, rarely, sometimes, often, or all the time. Change from baseline in physical Health domain score was reported in this outcome measure. Raw score for physical health domain were transformed to a scale ranged from 0 to 100, where lower scores denoted better physical health.
Secondary	Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9	Baseline (Day 1), Month 9	Haem-A-QoL: participant-reported questionnaire designed for adult participants (\>=17 years of age) with hemophilia; and consisted of 46 items comprising 10 domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality). Items were rated along five response options: never, rarely, sometimes, often, or all the time. Raw score for each domain were transformed to a scale ranged from 0 to 100, where lower scores denoted better health. Haem-A-QoL Total Score was average of all domain scores and ranged from 0 to 100, where lower scores denoted better quality of life.

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	NUMBER
PRIMARY	Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	MEAN
SECONDARY	Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	From Day 1 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	NUMBER
SECONDARY	Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	From Day 1 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	MEAN
SECONDARY	Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	NUMBER
SECONDARY	Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	MEAN
SECONDARY	Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	NUMBER
SECONDARY	Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period	From Day 29 up to Day 246 or up to the last day of bleeding follow up (any day up to Day 246), whichever was the earliest	Analysis was performed on ITT population.	episodes per participant per year	MEAN
SECONDARY	Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Month 9	Baseline (Day 1), Month 9	Analysis was performed on ITT population. Here, overall number of participants analyzed = participants evaluable for this outcome measure.	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9	Baseline (Day 1), Month 9	Analysis was performed on ITT population. Here, overall number of participants analyzed = participants evaluable for this outcome measure.	score on a scale	LEAST_SQUARES_MEAN

1 to 10 of 12Source ClinicalTrials.gov

See all 12 outcomes

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	Bypassing Agents (BPA) On-demand	18.071	95% Confidence Interval 10.598 to 30.812	episodes per participant per year
Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	Fitusiran 80 mg Prophylaxis	1.666	95% Confidence Interval 1.014 to 2.736	episodes per participant per year
Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	Bypassing Agents (BPA) On-demand	18.1	Standard Deviation 14.9	episodes per participant per year
Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period	Fitusiran 80 mg Prophylaxis	1.7	Standard Deviation 3.8	episodes per participant per year
Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	Bypassing Agents (BPA) On-demand	18.819	95% Confidence Interval 11.541 to 30.687	episodes per participant per year
Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	Fitusiran 80 mg Prophylaxis	2.024	95% Confidence Interval 1.306 to 3.138	episodes per participant per year
Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	Bypassing Agents (BPA) On-demand	18.8	Standard Deviation 15.4	episodes per participant per year
Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period	Fitusiran 80 mg Prophylaxis	2.0	Standard Deviation 3.7	episodes per participant per year
Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period	Bypassing Agents (BPA) On-demand	15.675	95% Confidence Interval 9.281 to 26.471	episodes per participant per year
Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period	Fitusiran 80 mg Prophylaxis	0.872	95% Confidence Interval 0.491 to 1.551	episodes per participant per year

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bypassing Agents (BPA) On-demand	19
Overall Study	STARTED	Fitusiran 80 mg Prophylaxis	38
Overall Study	Safety Analysis Set	Bypassing Agents (BPA) On-demand	19
Overall Study	Safety Analysis Set	Fitusiran 80 mg Prophylaxis	41
Overall Study	COMPLETED	Bypassing Agents (BPA) On-demand	19
Overall Study	COMPLETED	Fitusiran 80 mg Prophylaxis	33
Overall Study	NOT COMPLETED	Bypassing Agents (BPA) On-demand	0
Overall Study	NOT COMPLETED	Fitusiran 80 mg Prophylaxis	5

Source ClinicalTrials.gov

Adverse events80

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Alanine Aminotransferase Increased	Investigations	Bypassing Agents (BPA) On-demand	0	19	0
other	Alanine Aminotransferase Increased	Investigations	Fitusiran 80 mg Prophylaxis	13	41	23
other	Aspartate Aminotransferase Increased	Investigations	Bypassing Agents (BPA) On-demand	0	19	0
other	Aspartate Aminotransferase Increased	Investigations	Fitusiran 80 mg Prophylaxis	8	41	16
other	Blood Alkaline Phosphatase Increased	Investigations	Bypassing Agents (BPA) On-demand	0	19	0
other	Blood Alkaline Phosphatase Increased	Investigations	Fitusiran 80 mg Prophylaxis	5	41	9
other	Fibrin D Dimer Increased	Investigations	Bypassing Agents (BPA) On-demand	0	19	0
other	Fibrin D Dimer Increased	Investigations	Fitusiran 80 mg Prophylaxis	3	41	6
other	Gamma-Glutamyltransferase Increased	Investigations	Bypassing Agents (BPA) On-demand	0	19	0
other	Gamma-Glutamyltransferase Increased	Investigations	Fitusiran 80 mg Prophylaxis	6	41	9

1 to 10 of 80Source ClinicalTrials.gov

See all 80 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bypassing Agents (BPA) On-demand	0	19
Total, all-cause mortality	Fitusiran 80 mg Prophylaxis	0	41
Total, other adverse events	Bypassing Agents (BPA) On-demand	8	19
Total, other adverse events	Fitusiran 80 mg Prophylaxis	32	41
Total, serious adverse events	Bypassing Agents (BPA) On-demand	5	19
Total, serious adverse events	Fitusiran 80 mg Prophylaxis	7	41

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
34922648	DERIVED	PubMed
35114155	DERIVED	PubMed
37003287	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Bypassing Agents (BPA) On-demand vs Fitusiran 80 mg Prophylaxis: deaths from any cause	Trial comparisons
Bypassing Agents (BPA) On-demand vs Fitusiran 80 mg Prophylaxis: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03417102

GET https://conductscience.org/api/trials/v1/NCT03417102/results?page=2

API reference For AI assistants